Skip to content
Aarey Drugs & Pharmaceuticals logo

Aarey Drugs & Pharmaceuticals

AAREYDRUGS NSE
₹109.60 up 1.55 (1.43%)
Market Cap
₹311 Cr
P/E
74.56

Aarey Drugs & Pharmaceuticals (AAREYDRUGS) share price was ₹108.05 at the 28 Oct 2026 close; market capitalisation ₹306 Cr; P/E (TTM) 73.50; sector Healthcare. The share price rose 18.4% over the year to 28 Oct 2026 (adjusted for splits and bonuses). In the Jun 2026 quarter, revenue fell 56.3% year on year to ₹44.63 Cr and net profit fell 25.6% year on year to ₹1.02 Cr (compared with Jun 2025). Promoters held 41.45% of Aarey Drugs & Pharmaceuticals in Sep 2026, up 3.74 percentage points from Jun 2026. Its Tapetide Score is 42/100 (Weak) as of 28 Oct 2026.

Close 28 Oct 2026 ₹108.05 +14.94 +16.05% 1Y

Key Fundamentals

MicrocapPharmaceuticals & BiotechnologyHealthcare
Market Cap
₹311 Cr
P/E (TTM)
74.56
EBITDA
₹13.30 Cr
Return on Equity
2.64%
Debt to Equity
0.33
Book Value
₹53.28
EPS (TTM)
₹1.47
52W High
₹114.80
52W Low
₹50.31

Price-based figures as of 29 Oct 2026, 10:47 IST · EPS basis: Standalone · TTM

Peer Comparison

Healthcare › Pharmaceuticals

Sun Pharma
₹1,765.8035.034,23,675 Cr5.070.91%13.79%17.94%61,848 Cr12,117 Cr
Divis Laboratories
₹9,655.0087.632,56,310 Cr15.290.32%15.32%18.96%11,682 Cr2,925 Cr
Torrent Pharmaceuticals
₹4,609.0072.351,75,312 Cr9.540.82%12.16%9.06%17,058 Cr2,156 Cr
Laurus Labs
₹2,187.00108.051,18,166 Cr22.300.09%16.38%19.67%7,323 Cr1,090 Cr
Zydus Life Science
₹1,181.3026.291,17,835 Cr4.350.09%16.99%19.24%28,515 Cr4,593 Cr
Dr Reddys Laboratories
₹1,338.6034.671,11,730 Cr2.880.61%10.87%13.94%34,247 Cr3,184 Cr
Cipla
₹1,364.8032.701,10,257 Cr3.120.96%11.21%14.88%28,589 Cr3,356 Cr
Aarey Drugs & Pharmaceuticals (this company)
₹109.6074.56311 Cr2.060.00%2.64%6.84%421 Cr4 Cr
Median 8 companies₹1,565.3053.691,18,001 Cr4.710.47%12.98%16.41%22,787 Cr3,055 Cr

Comparable companies in the same industry. Market cap, P/E and P/B use the live price; other metrics are as reported in filings. A dash means the figure is not published for that company.

Tapetide Score

Data-driven rating, 0–100, as of . How it works →

42 Weak
Overall score

Data confidence 100/100

surveillance:ASM1

Category scores

Quality Good 58
Returns, margins, earnings quality 22% weight
Valuation Poor 29
Cheap vs sector & own history 24% weight
Growth Poor 27
Sales & profit trajectory 9% weight
Financial Health Weak 37
Solvency, leverage, coverage 9% weight
Momentum Strong 88
Trend strength, vol-adjusted 12% weight
Ownership Weak 39
FII/DII/promoter flows 24% weight

The Tapetide Score is data analysis, not investment advice. Tapetide is not a SEBI-registered research analyst or investment adviser.

Key Insights

Strengths

1
  • Promoter holding has increased by 5.08% over last quarter.

Weaknesses

6
  • Though the company is reporting repeated profits, it is not paying out dividend
  • Company has low interest coverage ratio.
  • The company has delivered a poor sales growth of 6.27% over past five years.
  • Company has a low return on equity of 3.13% over last 3 years.
  • Earnings include an other income of Rs.6.26 Cr.
  • Promoter holding has decreased over last 3 years: -7.25%

Technical Indicators

Oscillators

Neutral

Bearish
1
Neutral
7
Bullish
1

Overall

Bullish

Bearish
2
Neutral
7
Bullish
10

Moving Averages

Bullish

Bearish
1
Neutral
0
Bullish
9

Growth Rate

Revenue Growth
-1.12% lower than 3Y

change over 1 year

Net Income Growth
0% lower than 3Y

change over 1 year

Cash Flow Change
-1.55%

change over 1 year

EBITDA Margin Change
5.32%

change over 1 year Operating margin 2.96% · Jun 2026

Quarterly Results

Particulars Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Sales
50.96
57.83
76.48
210
127
105
134
108
102
84.16
96.43
189
44.63
Expenses
49.62
55.99
73.78
212
126
101
132
112
101
81.52
97.94
185
43.31
Operating Profit
1.34
1.84
2.7
-1.44
1.18
3.72
2.2
-4.21
1.71
2.64
-1.51
4.34
1.32
OPM %
2.63%
3.18%
3.53%
-0.68%
0.93%
3.54%
1.64%
-3.89%
1.67%
3.14%
-1.57%
2.29%
2.96%
Other Income
0.7
0.84
0.29
5.14
1.58
0.02
0.68
7.54
1.55
0.79
4.18
-0.43
1.72
Interest
0.42
0.41
0.47
0.4
0.96
0.49
0.58
1.3
1.04
1.26
0.92
1.78
1.67
Depreciation
0.89
1.27
1.06
1.15
0.47
1.51
0.9
0.41
0.49
0.69
0.83
0.85
0.85
PBT
0.73
1
1.46
2.15
1.33
1.74
1.4
1.62
1.73
1.48
0.92
1.28
0.52
Tax %
0%
-22%
30.14%
-0.47%
6.77%
8.62%
48.57%
71.6%
20.81%
31.08%
38.04%
-21.88%
-98.08%
Net Profit
0.72
1.23
1.02
2.15
1.24
1.6
0.72
0.47
1.37
1.02
0.57
1.56
1.02
EPS (₹)
0.28
0.48
0.4
0.77
0.44
0.57
0.25
0.17
0.48
0.36
0.2
0.55
0.36
Figures in ₹ Crores

Profit & Loss

Particulars Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026TTM
Sales
213
246
396
349
354
298
348
493
419
396
474
472
415
Expenses
212
245
386
342
347
294
344
481
411
391
471
465
408
Operating Profit
1
1
10
8
8
3
5
11
8
4
3
7
7
OPM %
0.6%
0.4%
2.4%
2.2%
2.2%
1.1%
1.3%
2.3%
1.8%
1.1%
0.6%
1.5%
1.6%
Other Income
3
3
3
3
4
7
7
3
3
7
10
6
6
Interest
1
2
4
2
2
2
2
2
3
4
5
5
6
Depreciation
1
1
1
1
1
1
1
2
2
2
2
3
3
PBT
1
2
8
8
9
7
8
10
6
5
6
5
4
Tax %
23%
29%
31%
25%
27%
20%
21%
35%
37%
12%
34%
27%
—
Net Profit
1
1
5
6
7
6
7
7
4
5
4
4
4
EPS (₹)
0.65
0.77
3.02
2.64
2.8
2.48
2.78
2.58
1.49
1.67
1.42
1.4
1.47
Div. Payout %
0%
0%
0%
0%
4%
0%
0%
0%
0%
0%
0%
0%
—
Figures in ₹ Crores

Balance Sheet

Particulars Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Equity Capital
17
17
18
23
23
23
23
25
25
28
28
28
Reserves
19
20
31
57
63
69
75
88
92
105
110
122
Borrowings
11
15
10
3
16
18
18
14
38
31
35
50
Other Liabilities
69
74
83
86
43
84
116
117
136
139
117
97
Total Liabilities
115
125
142
170
146
194
233
245
291
303
291
297
Fixed Assets
6
8
12
12
12
12
14
14
14
13
16
26
CWIP
0
0
0
0
0
0
0
0
0
0
0
0
Investments
0
0
0
0
0
0
0
0
0
1
2
2
Other Assets
109
117
130
157
133
181
218
230
277
289
272
269
Total Assets
115
125
142
170
146
194
233
245
291
303
291
297
Figures in ₹ Crores

Cash Flow

Particulars Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Operating
3
6
1
-20
1
3
5
0
-1
-3
10
10
Investing
-2
-3
-5
-1
-1
-1
-3
-3
0
-2
-6
-12
Financing
-2
-2
4
23
-2
-2
-2
2
1
6
-4
2
Net Cash Flow
-1
1
-1
2
-3
0
0
0
1
1
0
0
Free Cash Flow
1
3
-4
-21
-1
2
3
-2
-2
-4
5
-2
CFO/EBITDA
239
560
28
-232
37
135
154
36
13
-37
421
164
Figures in ₹ Crores

Ratios

Particulars Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Debtor Days
114
108
75
100
109
118
170
101
165
170
103
100
Inventory Days
7
3
5
16
23
21
20
11
26
33
36
33
Days Payable
117
108
71
84
40
98
120
86
115
123
81
66
Cash Conversion Cycle
5
3
9
32
92
42
69
26
76
80
58
68
Working Capital Days
49
40
34
69
77
99
91
68
89
106
89
90
ROCE %
7%
7%
22%
14%
12%
8%
9%
10%
6%
6%
6%
6%

Insights

Beta

AI-extracted from concalls & annual reports · figures as reported, with sources

Log in to view Aarey Drugs & Pharmaceuticals insights

66 extracted metrics + investor summaries across FY10–FY27.

Shareholding Pattern

DIIs1.44%Promot.41.45%FIIs4.27%Others12.63%Public40.20%As ofSep 2026

Documents

Frequently Asked Questions about Aarey Drugs & Pharmaceuticals

What does Aarey Drugs & Pharmaceuticals Ltd do?
Incorporated in 1990, Aarey Drugs & Pharmaceuticals Ltd is a manufacturer of API / Bulk Drugs and offers products for diverse industrial applications[1]
Where is Aarey Drugs & Pharmaceuticals Ltd (AAREYDRUGS) listed?
Aarey Drugs & Pharmaceuticals Ltd trades as AAREYDRUGS on the NSE and under code 524412 on the BSE.
Which sector does Aarey Drugs & Pharmaceuticals Ltd belong to?
Aarey Drugs & Pharmaceuticals Ltd is classified under the Healthcare sector, in the Pharmaceuticals industry.
What is the market capitalisation of Aarey Drugs & Pharmaceuticals Ltd?
Aarey Drugs & Pharmaceuticals Ltd has a market capitalisation of ₹310.76 Cr as of 29 Oct 2026, which places it in the Small Cap band.
What is the PE ratio of Aarey Drugs & Pharmaceuticals Ltd?
Aarey Drugs & Pharmaceuticals Ltd trades at a PE ratio of 74.56 as of 29 Oct 2026, on earnings per share of ₹1.47, against a book value of ₹53.28 per share.
What is the 52-week high and low of Aarey Drugs & Pharmaceuticals Ltd?
Over the last 52 weeks Aarey Drugs & Pharmaceuticals Ltd has traded between ₹50.31 and ₹114.8 as of 29 Oct 2026.
What is the Return on Equity (ROE) of Aarey Drugs & Pharmaceuticals Ltd?
Aarey Drugs & Pharmaceuticals Ltd reported a return on equity of 2.64%. Its debt-to-equity ratio is 0.33.

Company Information

Incorporated in 1990, Aarey Drugs & Pharmaceuticals Ltd is a manufacturer of API / Bulk Drugs and offers products for diverse industrial applications[1]

Website aareydrugs.com
CEO Mr. Mihir Rajesh Ghatalia B.E
Listed 2021-08-06
Face Value ₹ 10
Shares Outstanding 2,83,54,303

For AI agents and developers

Reading this as an AI agent, LLM or automated pipeline? Every page on Tapetide is also published as clean Markdown — no navigation, no scripts, just the data. Fetch https://tapetide.com/stocks/AAREYDRUGS.md for Aarey Drugs & Pharmaceuticals Ltd: company profile, latest price, key fundamentals, the Tapetide Score, growth rates, quarterly and annual financial statements, shareholding pattern, technical indicators, analyst ratings and exchange filings.

Append .md to any Tapetide URL for the same treatment. A full index of what we publish is at /llms.txt and /llms-full.txt. For live, structured queries instead of documents, use our Indian stock market MCP server.

Explore More

More Pharma stocks → FII DII DataStock ScreenerNifty 50 HeatmapF&O Ban ListFII and DII flows, month by monthHow Tapetide Scores changed, month by monthStocks mutual funds are buying, month by month